利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.025 秒)

    STAT3 ANTAGONISTS AND THEIR USES AS VACCINES AGAINST CANCER
    3.
    发明申请
    STAT3 ANTAGONISTS AND THEIR USES AS VACCINES AGAINST CANCER 审中-公开
    STAT3拮抗剂及其作为疫苗的疫苗使用

    公开(公告)号：US20100297061A1

    公开(公告)日：2010-11-25

    申请号：US12611732

    申请日：2009-11-03

    申请人： Hua Yu ,  Drew Pardoll ,  Richard Jove

    发明人： Hua Yu ,  Drew Pardoll ,  Richard Jove

    IPC分类号： A61K38/19 ,  A61P35/00 ,  A61K39/00 ,  A61P31/04 ,  A61P31/10 ,  A61P31/12 ,  A61P33/02 ,  A61P33/10

    CPC分类号： C07K16/18 ,  A61K39/0011 ,  A61K48/00 ,  A61K2039/5152 ,  A61K2039/5154 ,  A61K2039/55522 ,  C12N5/0693 ,  C12N2501/60

    摘要： The present invention relates to methods for treating and/or preventing cancer. In particular the present invention relates to ex vivo immunotherapeutic methods. The methods comprise decreasing Stat3 (signal transducer and activator of transcirption3) expression and/or function in tumor cells and the administration of such cells to a subject in need of treatment and/or prevention. Other methods of the invention comprise activation T-cells by co-culturing the T-cells with the tumor cells with decreased Stat3 expression or function. The invention further encompasses methods comprising decreasing Stat3 expression or function in antigen-presenting cells and co-administering tumor cells and the antigen-presenting cells with decreased Stat3 function to a patient. The invention further relates to methods for stimulating dendritic cell differentiation.

    摘要翻译： 本发明涉及治疗和/或预防癌症的方法。 特别地，本发明涉及离体免疫治疗方法。 所述方法包括降低肿瘤细胞中Stat3（信号转导和转录激活因子3）的表达和/或功能，并将此类细胞施用于需要治疗和/或预防的受试者。 本发明的其它方法包括通过与具有降低的Stat3表达或功能的肿瘤细胞共培养T细胞来活化T细胞。 本发明还包括降低Stat3在抗原呈递细胞中的表达或功能的降低，并且向患者共同施用具有降低的Stat3功能的肿瘤细胞和抗原呈递细胞。 本发明还涉及刺激树突状细胞分化的方法。

    Stat3 antagonists and their use as vaccines against cancer
    4.
    发明授权
    Stat3 antagonists and their use as vaccines against cancer 有权
    Stat3拮抗剂及其作为疫苗的用途

    公开(公告)号：US07638122B2

    公开(公告)日：2009-12-29

    申请号：US10383707

    申请日：2003-03-07

    申请人： Hua Yu ,  Drew Pardoll ,  Richard Jove

    发明人： Hua Yu ,  Drew Pardoll ,  Richard Jove

    IPC分类号： A61K35/12 ,  A61K35/14 ,  A61K41/00

    CPC分类号： C07K16/18 ,  A61K39/0011 ,  A61K48/00 ,  A61K2039/5152 ,  A61K2039/5154 ,  A61K2039/55522 ,  C12N5/0693 ,  C12N2501/60

    摘要： The present invention relates to methods for treating and/or preventing cancer. In particular the present invention relates to ex vivo immunotherapeutic methods. The methods comprise decreasing Stat3 (signal transducer and activator of transcription3) expression and/or function in tumor cells and the administration of such cells to a subject in need of treatment and/or prevention. Other methods of the invention comprise activating T-cells by co-culturing the T-cells with the tumor cells with decreased Stat3 expression or function. The invention further encompasses methods comprising decreasing Stat3 expression or function in antigen-presenting cells and co-administering tumor cells and the antigen-presenting cells with decreased Stat3 function to a patient. The invention further relates to methods for stimulating dendritic cell differentiation.

    摘要翻译： 本发明涉及治疗和/或预防癌症的方法。 特别地，本发明涉及离体免疫治疗方法。 所述方法包括降低Stat3（信号转导和转录激活因子3）在肿瘤细胞中的表达和/或功能，并将此类细胞施用于需要治疗和/或预防的受试者。 本发明的其它方法包括通过与具有降低的Stat3表达或功能的肿瘤细胞共培养T细胞活化T细胞。 本发明还包括降低Stat3在抗原呈递细胞中的表达或功能的降低，并且向患者共同施用具有降低的Stat3功能的肿瘤细胞和抗原呈递细胞。 本发明还涉及刺激树突状细胞分化的方法。

    Irradiated tumor cell vaccine engineered to express GM-CSF
    10.
    发明授权
    Irradiated tumor cell vaccine engineered to express GM-CSF 失效
    辐射肿瘤细胞疫苗工程化以表达GM-CSF

    公开(公告)号：US5637483A

    公开(公告)日：1997-06-10

    申请号：US265554

    申请日：1994-06-23

    申请人： Glenn Dranoff ,  Richard C. Mulligan ,  Drew Pardoll

    发明人： Glenn Dranoff ,  Richard C. Mulligan ,  Drew Pardoll

    IPC分类号： A61K39/00 ,  A61K39/21 ,  A61K48/00 ,  C12N15/00

    CPC分类号： A61K39/21 ,  A61K39/0011 ,  A61K39/12 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/55522 ,  A61K48/00 ,  C12N2740/13043

    摘要： A method of altering the specific, systemic immune response of an individual to a target antigen by the co-administration of a cytokine an adhesion or accessory molecule and the target antigen. The target antigen may be a tumor cell, a tumor cell antigen, an infectious agent or other foreign antigen, or other antigens to which an enhanced systemic immune response is desirable. Alternatively, the antigen may be a non-foreign antigen when a suppression of a systemic immune response is desired. The resulting systemic immune response is specific for the target antigen.

    摘要翻译： 通过共同施用细胞因子粘附或辅助分子和靶抗原来改变个体对靶抗原的特异性全身免疫应答的方法。 靶抗原可以是肿瘤细胞，肿瘤细胞抗原，感染因子或其它外来抗原，或其它需要增强的全身免疫应答的抗原。 或者，当需要抑制全身免疫应答时，抗原可以是非外源抗原。 所产生的全身免疫应答对靶抗原是特异性的。